Wesley M. Jackson, Ph.D. (Founder, Acting CEO, and Chief Science Officer) has been actively involved in biotechnology entrepreneurship for nearly 10 years. Since founding Valitor, Wesley has been the principal investigator of five NIH projects to optimize the manufacturing, characterization, and formulation of multivalent protein conjugate drugs and to evaluate their performance in relevant disease models.
Kevin E. Healy, Ph.D. (Founder and Corporate Director) is currently a UC Berkeley Professor of Bioengineering with over 25 years of research developing biomaterials-based biotechnologies. Kevin has pursued the commercialization of these technologies by founding BioEngineered Materials, Inc., Cardiomimetics, Inc., and most recently, mOrganos, Inc. He continues to maintain active collaborations with clinicians in a variety of medical specialties, and he is a consultant to the biotechnology industry.
David V. Schaffer, Ph.D. (Founder and Corporate Director) is currently a UC Berkeley Professor of Chemical Engineering and has over 20 years of research with specific expertise in molecular engineering of biologics-based, gene and stem cell therapeutics for tissue regeneration, which has resulted in more than 12 biotechnology patents. He is also a co-founder and director of 4D Molecular Therapeutics, Inc. and IGNITE Immunotherapy, Inc.